touchNEUROLOGY - Online Education for Neurologists

Time 2021-08-08 21:24:22

Web Name: touchNEUROLOGY - Online Education for Neurologists

WebSite: http://www.touchneurology.com

ID:186129

Keywords:

Online,touchNEUROLOGY,Education,

Description:

Trending Across touchNEUROLOGY At a glance: education, conference reports and articles Epilepsy, Huntington’s Disease touchEXPERT OPINIONS Can we reach our goals for seizure management in drug-resistant focal epilepsy? Dr Christian Brandt, Dr Manuel Toledo, Prof. Louise Tyvaert Watch Time: 32 mins Available in: Watch leading experts discuss aspects of the diagnosis and treatment of drug-resistant epilepsy, including up-to-date clinical data. Learning objectives Learning Objectives Recognize the impact of recurrent seizures in patients with drug-resistant epilepsy Outline the challenges associated with current standard of care approaches in the management of patients with drug-resistant epilepsy Assess how emerging anti-epileptic drugs might address the unmet treatment needs in patients with drug-resistant focal epilepsy View All Parkinson's Disease touchEXPERT OPINIONS Looking back over 2018: What have we learnt about optimizing the treatment of advanced Parkinson s disease? Prof. Angelo Antonini, Prof. Ray Chaudhuri, Dr Rich Helmich, Prof. Heinz Reichmann Watch Time: 63 mins Watch a series of internationally renowned clinical specialists from Europe discuss pivotal data for Parkinson’s disease from key neurology congresses throughout 2018 and consider how these findings may affect clinical practice.The potential implications of these data for optimizing outcomes for patients with advanced Parkinson’s disease are explored from both global and regional perspectives. Learning objectives Learning Objectives Summarize the latest clinical data for emerging treatment options and treatment delivery systems for the management of motor and non-motor symptoms of Parkinson’s disease. Discuss the use of biomarkers for the early identification of Parkinson’s disease, and to facilitate the use of neuroprotective agents. Describe the use of emerging targeted agents and therapeutic strategies to manage treatment side effects and maintain patient quality of life. View All Multiple Sclerosis Lawrence Steinman EAN, 2021: Results from the Phase 3 ULTIMATE I and II Trials It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA), to discuss the results from the Phase 3 ULTIMATE I and II trials, investigating ublituximab versus teriflunomide in relapsing multiple sclerosis. The abstract entitled: ‘Ublituximab versus teriflunomide [ ] View All Neuromuscular Diseases Renato Mantegazza, EAN 2021: Phase 3 ADAPT Study Results touchNEUROLOGY met with Renato Mantegazza (Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milan, Italy), to discuss the phase 3 ADAPT study results investigating efgartigimod for the treatment of myasthenia gravis. The abstract entitled: ‘Safety and Tolerability of Efgartigimod in Patients with Generalized Myasthenia Gravis: Phase 3 ADAPT Study Results’ was [ ] View All Headache Disorders Andrew Blumenfeld, AHS 2021: Combination use of OnabotulinumtoxinA and CGRP mAbs for Chronic Migraine We had the great pleasure of meeting with Andrew Blumenfeld (Director, Headache, The Neurology Center of Southern California, Carlsbad, CA, USA) to discuss the combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine. The abstract ‘Combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine’ was presented at [ ] View All Multiple Sclerosis Patrick Vermersch, EAN 2021: Tolebrutinib in Patients with Progressive Multiple Sclerosis: Phase 3 PERSEUS and HERCULES Trials It was a pleasure to meet with Patrick Vermersch (University of Lille, Lille, France) to discuss the use of tolebrutinib in patients with progressive multiple sclerosis. The abstract entitled: ‘BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials’ was presented at the 7th Congress of the European Academy [ ] View All Headache Disorders The Italian Chapter of the MOST Project: Specific Changes in the Organization of Headache Centres Can Help Improve the Patient Journey Lorenzo Chiodo, Elisabetta Grillo, Elia Lahouiri touchREVIEWS in Neurology. 2021;17(1):48-52 In 2018, the Global Burden of Disease study placed headache disorders as the second leading cause of years lived with disability.1 As another indicator of its burden, headache was ranked among the leading causes of years lived with disability.1 Given its prevalence and severe symptom burden, headache has a consequential negative impact on the quality of life [ ] View All Parkinson's Disease Opicapone: From Preclinical Data to Real-world Evidence Heinz Reichmann touchREVIEWS in Neurology. 2021;17(1):32-5 Parkinson’s disease is now considered to be a spreading disease caused by the aggregation of abnormal alpha-synuclein.1 According to Braak et al., in stage I of the disease, alpha-synuclein pathology is found in the olfactory bulb and the dorsal nucleus of the vagus nerve,2 as well as in the enteric nervous system (Auerbach’s and Meissner’s plexuses).3 These observations [ ] View All Neuropathic Pain Regional Techniques and Interventions for Intractable Neuropathic Pain May L Chin touchREVIEWS in Neurology. 2021;17(1):16-22 Neuropathic pain arises from injury to or disease in the somatosensory nervous system.1 Normal sensation and pain sensation are both impaired and patients may present with peculiar painful characteristics such as allodynia and hyperalgesia.2 Central neuropathic pain includes pain from spinal cord injury and demyelinating diseases of the spinal cord, such as multiple sclerosis.1 Lesions or disease of [ ] View All Parkinson's Disease Development, Efficacy and Safety of Once-daily, Bedtime, Extended-release Amantadine (Gocovri®) to Treat Dyskinesia and OFF Time in Parkinson’s Disease Stuart H Isaacson, Kelly E Lyons, Fahd Amjad touchREVIEWS in Neurology. 2021;17(1):36-47 Parkinson’s disease is a progressive synucleinopathy that causes widespread neurodegeneration.1 It is estimated to affect approximately 6.1 million people globally and 0.7–1.0 million people in the USA.2–4 The incidence of the disease is expected to continue to increase over time, and with it, the burden to healthcare systems.3,4 The cardinal motor symptoms, which reflect nigral dopaminergic degeneration, are bradykinesia, [ ] View All Epilepsy, Huntington’s Disease touchEXPERT OPINIONS Can we reach our goals for seizure management in drug-resistant focal epilepsy? Dr Christian Brandt, Dr Manuel Toledo, Prof. Louise Tyvaert Watch Time: 32 mins Available in: Watch leading experts discuss aspects of the diagnosis and treatment of drug-resistant epilepsy, including up-to-date clinical data. Learning objectives Learning Objectives Recognize the impact of recurrent seizures in patients with drug-resistant epilepsy Outline the challenges associated with current standard of care approaches in the management of patients with drug-resistant epilepsy Assess how emerging anti-epileptic drugs might address the unmet treatment needs in patients with drug-resistant focal epilepsy Parkinson's Disease touchEXPERT OPINIONS Looking back over 2018: What have we learnt about optimizing the treatment of advanced Parkinson s disease? Prof. Angelo Antonini, Prof. Ray Chaudhuri, Dr Rich Helmich, Prof. Heinz Reichmann Watch Time: 63 mins Watch a series of internationally renowned clinical specialists from Europe discuss pivotal data for Parkinson’s disease from key neurology congresses throughout 2018 and consider how these findings may affect clinical practice.The potential implications of these data for optimizing outcomes for patients with advanced Parkinson’s disease are explored from both global and regional perspectives. Learning objectives Learning Objectives Summarize the latest clinical data for emerging treatment options and treatment delivery systems for the management of motor and non-motor symptoms of Parkinson’s disease. Discuss the use of biomarkers for the early identification of Parkinson’s disease, and to facilitate the use of neuroprotective agents. Describe the use of emerging targeted agents and therapeutic strategies to manage treatment side effects and maintain patient quality of life. More From The Conference Hub View All View highlights and coverage from leading international Neurology congresses Latest Journal Articles View All Read the latest articles from our peer reviewed Neurology journals published by touchNEUROLOGY Neuropathic Pain Functional and Pain Improvement in Tennis Elbow with Dry Needling as Alternative Treatment: Case Series Deby Wahyuning Hadi, Henry Sugiharto, Amanda Tiksnadi touchREVIEWS in Neurology. 2021;17(1):60-3 Lateral epicondylitis, or tennis elbow, is pain in the lateral elbow as a result of repetitive forearm pronation and supination in elbow extension.1 It is a frequent cause of elbow pain, and affects 1–3% of the adult population every year, resulting in decreased productivity and economic losses.2,3 Equally present in males and females, it mostly occurs between [ ] Neurosurgery Lumbar Puncture: Indications, Challenges and Recent Advances Biswamohan Mishra, Venugopalan Y Vishnu touchREVIEWS in Neurology. 2021;17(1):23–31 Studying cerebrospinal fluid (CSF) is essential for diagnosing many central nervous system (CNS) diseases, including infection, inflammation and malignancy. Lumbar puncture is a relatively safe and routinely performed procedure for extracting CSF.1 In this review, we summarize the essential CSF flow dynamics, common indications and contraindications for lumbar puncture, and describe the procedures to rule out [ ] Neuromuscular Diseases, Neuroimmunology Foreword touchREVIEWS in Neurology, Volume 17, Issue 1, 2021 Welcome to touchREVIEWS in Neurology, our newly-named journal, previously US Neurology. The decision to expand the scope of the journal was taken after an excellent year for touchNEUROLOGY. We feel that in an increasingly global research community, submissions were limited by an assumed primary reach to one regional audience. By taking on submissions from the [ ] Parkinson's Disease Development, Efficacy and Safety of Once-daily, Bedtime, Extended-release Amantadine (Gocovri®) to Treat Dyskinesia and OFF Time in Parkinson’s Disease Stuart H Isaacson, Kelly E Lyons, Fahd Amjad touchREVIEWS in Neurology. 2021;17(1):36-47 Parkinson’s disease is a progressive synucleinopathy that causes widespread neurodegeneration.1 It is estimated to affect approximately 6.1 million people globally and 0.7–1.0 million people in the USA.2–4 The incidence of the disease is expected to continue to increase over time, and with it, the burden to healthcare systems.3,4 The cardinal motor symptoms, which reflect nigral dopaminergic degeneration, are bradykinesia, [ ] Want To Know More About Our Journals? Taking a balanced and practical view of the current clinical landscape in Neurology is at the heart of touchNEUROLOGY and the journals we produce. The European Neurological Review and US Neurology are free-to-access, peer reviewed journals that aim to provide balanced and objective articles relevant to the day-to-day clinical setting. Learn more about our journals Society Congress Partners View All touchNEUROLOGY is proud to partner with leading medical societies and congresses from around the world to bring you news and insight from virtual and live events accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down Clicky Media Logoconsultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72

TAGS:Online touchNEUROLOGY Education 

<<< Thank you for your visit >>>

touchNEUROLOGY provide learning resources for neurologists, as well as CME-accredited and independent learning activities. Find out more here

Hot Websites